foxo4-dri senolytic human trial Results: What to Expect (2026) FOXO4-DRI induces keloid senescent fibroblast

P.MilardiD.BorzelliD.DE MarchisC.DAvellaA.et al

Our commitment to transparency includes publication of assay results, purity verification, identity confirmation, endotoxin testing, microbial screening, elemental impurity analysis and molecular mass verification

The result is that improvements in gut symptom burden, mucosal integrity, and post-meal function often begin within the first 7 to 14 days of the protocol

Shortening the interval between injections brought about sustained symptoms of supraphysiological markers of excess free testosterone, oestradiol and dihydrotestosterone

These findings may help explain historical interest in pain and withdrawal research, but they do not establish an opioid-like clinical effect in people

BPC-157 does not cause traditional tolerance or require post-cycle therapy like hormonal compounds